# Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants

> **NCT01081847** · PHASE1 · COMPLETED · sponsor: **Malaria Vaccine and Drug Development Center** · enrollment: 40 (actual)

## Conditions studied

- Malaria, Vivax

## Interventions

- **DRUG:** Peptides (N,R&C) formulated in Montanide ISA 720
- **DRUG:** Peptides (N,R&C) formulated in Montanide ISA 51
- **DRUG:** Peptides (N,R&C) formulated in Montanide ISA 720
- **DRUG:** Peptides (N,R&C) formulated in Montanide ISA 51
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01081847
- **Lead sponsor:** Malaria Vaccine and Drug Development Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-03
- **Final completion:** 2006-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081847, "Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01081847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*